Aurobindo Pharma shares jumped more than 2% after brokerage firm BOCAPS upgraded the company’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share.
Eugia’s sales goal of about US$ 700 million by FY26E is seen as achievable. Furthermore, the EBITDA margin is expected to increase from 20% in FY24 to 24% in FY27.
As of 12:47 pm, Aurobindo Pharma shares were trading 2.05% higher at Rs 1,496.05 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
